Newsletter mensile Aiom
Anno V – Numero 45, Luglio 2022
Comitato scientifico editoriale: Vanna Chiarion Sileni, Paola Queirolo
Editore: Intermedia, Direttore Responsabile: Mauro Boldrini
Notizie dalla ricerca

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Neoadjuvant ipilimumab and nivolumab induces high pathologic response rates (pRRs) in clinical stage III nodal melanoma, and pathologic response is strongly associated with prolonged relapse-free survival (RFS). The PRADO extension cohort of the OpACIN-neo trial ( NCT02977052 ) addressed the feasibility and effect on clinical outcome of using pathologic response after neoadjuvant ipilimumab and nivolumab as a criterion for further treatment personalization …
Continua a leggere


Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update

ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options …
Continua a leggere


Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment

The first randomized trial of adjuvant treatment with checkpoint inhibitor in stage II melanoma reported a significant reduction in risk of tumor recurrence. This study evaluates two independent data sets to further document survival probabilities for patients with primary stage I and II melanoma. The Central Malignant Melanoma Registry (CMMR) in Germany evaluated 17,544 patients with a primary diagnosis of stage I and II melanoma from 2000 to 2015. The exploratory cohort consisted of 6,725 patients from the Center for Dermato-Oncology at the  …
Continua a leggere


Exploring supportive care and information needs through a proposed eHealth application among melanoma patients undergoing systemic therapy: a qualitative study

During and after systemic therapy, patients with high risk and advanced melanoma experience challenges regarding cancer-related symptoms, treatment-related adverse events, and an impact of these symptoms on their physical and psychosocial well-being. Few studies have investigated the specific needs of these patients and the potential role of eHealth applications in meeting those needs.To explore the supportive care and information needs of high risk and advanced melanoma patients, and how these needs can be supported by eHealth applications  …
Continua a leggere

Circulating Tumor DNA Testing Supports Rapid Therapeutic Decision-Making in Metastatic Melanoma: A Case Report

Treatment of metastatic melanoma includes the option of targeted therapy in patients with driver BRAF mutations. BRAF-MEK inhibitor drugs improve survival in the approximately 50% of patients with melanoma that harbor BRAF mutations. As BRAF mutation detection in tissue often takes days to weeks, it is not always possible or timely to obtain BRAF status in tissue using immunohistochemistry or next generation sequencing. Plasma-derived circulating tumor DNA (ctDNA) is a potential …
Continua a leggere


Appuntamenti Aiom

Avviso a tutti i Soci

A causa del protrarsi dell’emergenza coronavirus e delle relative disposizioni, si suggerisce di verificare la conferma dei singoli eventi direttamente con gli organizzatori

Management delle tossicità emergenti da farmaci innovativi (SMART)
FAD, 22 settembre, 20 ottobre 2022

Comunicare il cancro, la medicina e la salute
FAD, giugno – dicembre 2022

Artificial Intelligence meets Medical Oncology
I mercoledì dell’oncologia

Webinar, 13 luglio 2022

Diritto all’oblio oncologico
FAD, 14 luglio 2022

Medicina di precisione: Evoluzione nel trattamento dei tumori del colon retto
Webinar, 14 luglio 2022

HER2: le molteplici espressioni del marcatore e nuovi scenari terapeutici
I mercoledì dell’oncologia

Webinar, 20 luglio 2022

Questi e altri appuntamenti si possono consultare sul sito AIOM:

© 2020 Editore: 
Intermedia srl Via Lunga 16a Brescia, BS 25124 Italy
tel. 030 226105 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001
Iscrizione al Registro degli Operatori di Comunicazione N. 4867

Per contattare la redazione e commentare le notizie clicca qui
Per consultare i numeri arretrati della newsletter clicca qui

Ricevi questa email perché sei iscritto alla newsletter AIOM Cancellati

“Si ringrazia Pierre Fabre Pharma s.r.l. per il supporto incondizionato”